Pharsight

1. List of Sublocade drug patents

Application	Filing Date	Opposition Party	Legal Status
EP15828368A	2021-03-30	ELKINGTON AND FIFE LLP	Granted and Under Opposition
EP11728037A	2018-10-10	Teva Pharmaceutical Industries Ltd.	Opposition rejected

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10198218	INDIVIOR INC	Injectable flowable composition comprising buprenorphine	Jun, 2031 (8 years from now)
US9272044	INDIVIOR INC	Injectable flowable composition buprenorphine	Jun, 2031 (8 years from now)
US9498432	INDIVIOR INC	Injectable flowable composition comprising buprenorphine	Jun, 2031 (8 years from now)
US10592168	INDIVIOR INC	Injectable flowable composition comprising buprenorphine	Jun, 2031 (8 years from now)
US9827241	INDIVIOR INC	Injectable flowable composition comprising buprenorphine	Jun, 2031 (8 years from now)
US9782402	INDIVIOR INC	Injectable composition comprising buprenorphine	Jun, 2031 (8 years from now)
US10558394	INDIVIOR INC	Injectable flowable composition comprising buprenorphine	Jun, 2031 (8 years from now)
US8975270	INDIVIOR INC	Injectable flowable composition comprising buprenorphine	Sep, 2031 (8 years from now)
US8921387	INDIVIOR INC	Injectable flowable composition comprising buprenorphine	Jan, 2032 (8 years from now)
US11000520	INDIVIOR INC	Buprenorphine dosing regimens	Nov, 2035 (12 years from now)
US10646484	INDIVIOR INC	Methods to treat opioid use disorder	Jun, 2038 (15 years from now)

Do you want to check out SUBLOCADE patents from before 2022?

Market Authorisation Date: 30 November, 2017

Treatment: Treatment of moderate to severe opioid use disorder; Treating opioid addiction by administering buprenorphine; Treating opioid addiction by administering buprenorphine once per month; Treating opioid ...

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS